Soros Fund Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Soros Fund Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-14,933	Closed	-$268K	–	463
2014 Q1	$268K	Buy	+14,933	New	+$245K	﹤0.01%	297

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Soros Fund Management's CASC Position: Q2 2014 in Review

Soros Fund Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2014, closing a stake of 14,933 shares — an estimated $268K sold.

Soros Fund Management first reported a position in CASC in Q1 2014 and held it in 1 quarter. The position peaked at $268K in Q1 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q2 2014.

Soros Fund Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
Soros Fund Management sold 14,933 Cascadian Therapeutics, Inc. shares in Q2 2014, an estimated $268K.
Soros Fund Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
Soros Fund Management's Cascadian Therapeutics, Inc. position peaked at $268K in Q1 2014.
86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2014.

Based on Soros Fund Management's 13F filing for Q2 2014, filed 14 Aug 2014.